Martin Shkreli, center, appears with two members of his legal team in this August 2017 file photo. (Photo: Peter Foley/BB)
Martin Shkreli, the pharmaceutical industry's enfant terrible, was sentenced Friday to seven years in prison, putting an end to a saga that captivated and sometimes enraged Washington, Wall Street and the tabloids.
The brash 34-year-old — who gained notoriety for jacking up the price of a life-saving anti-infection drug — was convicted in August of lying to investors in his hedge funds and manipulating shares in Retrophin Inc., a biotech company he founded. Prosecutors sought a sentence of at least 15 years for the securities fraud. Shkreli, who once proclaimed "you can't quell the Shkrel," asked for as little as a year.
"This case is not about Mr. Shkreli's self-cultivated public persona," U.S. District Judge Kiyo Matsumoto in Brooklyn, New York, said Friday before handing down the sentence. His actions were "extremely serious," she said, recounting how he boasted once of threatening an investor and his family.
A remorseful Shkreli told the court he was embarrassed and ashamed, saying he got innocent people mixed up in his conduct. "This is my fault," he said. Addressing his investors, he choked back tears to say, "I am terribly sorry I lost your trust. You deserved far better."
"There is no conspiracy to take down Martin Shkreli," he said. "I took down Martin Shkreli, with my shameful and disgraceful actions."
Shkreli's downfall marks an ignominious end to what was once a promising career at the intersection of finance and pharma. The child of working-class immigrants from Albania and Croatia, Shkreli landed his first job as a 17-year-old college intern for Jim Cramer, the hedge fund manager and host of CNBC's "Mad Money." He was soon recommending that investors short biotech shares, becoming so good at it that he found himself under the scrutiny of the Securities and Exchange Commission at 19. The agency found nothing amiss.
He opened his first hedge fund at 23, then launched Retrophin five years later. In 2015, Shkreli infamously hiked — by 5,000% — the price of Daraprim, a life-saving drug for people with compromised immune systems. He has repeatedly maintained that his primary concern was company profit and investor returns. But detractors accused him of making the drug unaffordable to patients, many of them with HIV, while at the same time gouging insurance companies.
Less than a year later, the U.S. indicted him, accusing Shkreli of running his funds like Ponzi schemes. The evidence showed that Shkreli lied to investors over six years, by hiding the collapse of one fund and the near failure of a second, and by claiming to manage more than $125 million, when the real figure was closer to $1.1 million. He was also convicted of a separate scheme to secretly control Retrophin shares, but cleared of stealing company assets.
